Clinical trial
A Study of TAS-120 in Patients With Metastatic Breast Cancer
NCT04024436 · Taiho Oncology, Inc., Industry · Terminated
Key facts
| NCT number | NCT04024436 |
|---|---|
| Title | A Study of TAS-120 in Patients With Metastatic Breast Cancer |
| Official title | A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications |
| Lead sponsor | Taiho Oncology, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification |
| Intervention type | Drug |
| Interventions | Futibatinib, Futibatinib plus Fulvestrant |
| Enrollment | 64 |
| Start date | Jan 28, 2020 |
| Primary completion | May 31, 2023 |
| Completion | Sep 6, 2023 |
| First posted | Jul 18, 2019 |
| Last update posted | Nov 13, 2025 |
| Countries | Canada, France, Italy, Portugal, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: